Chinese drugmakers playing part in COVID-19 battle

20 February 2023
china_shanghai_big

Drug regulators in China are focusing on approving homegrown antiviral therapies with the ability to tackle new COVID-19 variants, according to analysis from a data and analytics provider.

The findings have been presented following Chinese regulator the National Medical Products Administration’s (NMPA) conditional approval of two homegrown oral drugs, Simcere Pharmaceutical’s (HKG: 2096) Xiannuoxin (simnotrelvir/ritonavir) and Shanghai Junshi Biosciences' (SHA: 688180) Mindevir (Deuterium remidevir tablets) for the treatment of mild to moderate COVID-19.

'Very limited antiviral drugs'

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical